Search

Your search keyword '"Ben M'Barek, R."' showing total 16 results
Start Over Author "Ben M'Barek, R."
16 results on '"Ben M'Barek, R."'

6. La Sciatique Paralysante

Author

Abdelmoula, L., primary, Ben M'Barek, R., additional, Belhajyahia, C.-H., additional, Chaabouni, L., additional, Testouri, N., additional, and Zouari, R., additional

Published
2006
Full Text
View/download PDF

13. [Bisphosphonates: indications in bone diseases other than osteoporosis].

Author

Abdelmoula LC, Ben M'barek R, Ben Hadj Yahia C, Tekaya R, Testouri N, Chaabouni L, and Zouari R

Subjects
Humans, Osteoporosis drug therapy, Bone Diseases drug therapy, Diphosphonates therapeutic use
Abstract

Aim: Report of bisphosphonates indications for osseous diseases other than osteoporosis., Methods: Narrative review of the literature., Results: Bisphosphonates represent a new medication which is increasingly used. Besides osteoporosis, it is indicated as first choice in different bone diseases such as Paget's disease and the prevention of bone complications in tumoral osteolysis. Bisphosphonates' efficiency has been proven in other pathologies: the fibrous dysplasia and the osteogenesis imperfecta. More over, many studies are driven having for goal to show the efficiency of bisphosphonates in the algoneurodystrophy, non corticosteroid-treated osteoporosis in chronic inflammatory rheumatism and aseptic osteonecrosis., Conclusion: Bisphosphonates are a powerful inhibition of osseous resoption frestable indicated for osteoporosis. Their indications were retended to paget's disease, malignant hypercalcemia, and osseous complications of malignant osterlysis.

Published
2011

14. [Update in treatment of psoriatic arthritis].

Author

Abdelmoula LC, Ben M'Barek R, Yahia CB, Tekaya R, Testouri N, Chaabouni L, and Zouari R

Subjects
Adalimumab, Alefacept, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Dermatologic Agents therapeutic use, Humans, Isoxazoles therapeutic use, Leflunomide, Recombinant Fusion Proteins therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy
Abstract

Psoriatic arthritis is a chronic rheumatic disease making part of spondylarthropathies. It is the most frequent chronic inflammatory rheumatism after rheumatoid arthritis. Eventhough, it is usually a benign affection, it may be destructive leading to handicap. Several new medications have been introduced, including anti-tumor necrosis factor (TNF alpha blockers) and leflunomide for treatment of psoriatic arthritis. Many studies show the efficacy of these medications in this disease.

Published
2008

15. [Treatment of reactive arthritis with infliximab].

Author

Abdelmoula LC, Yahia CB, Testouri N, Tekaya R, Ben M'barek R, Chaabouni L, and Zouari R

Subjects
Adult, Arthritis, Reactive microbiology, Chlamydia Infections complications, Humans, Infliximab, Male, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Reactive drug therapy
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results